Navigation Links
AuraSense Therapeutics Closes Tranche II of Series B Equity Investment
Date:7/31/2013

SKOKIE, Ill., July 31, 2013 /PRNewswire/ -- AuraSense Therapeutics, a biopharmaceutical company commercializing spherical nucleic acid (SNA™) constructs as gene regulation and modulation agents for a variety of diseases, including applications in oncology, dermatology, neurology, and for immune disorders, has closed the second tranche of its Series B financing.  The investment adds to the initial Series B round completed in December 2011.  Investors in the Series B round include AbbVie, Inc.  Other key individual investors in the round include Patrick Ryan, founder of Aon; David Walt, co-founder of Illumina; Boon Hwee Koh, Director of Agilent Technologies and former Chairman of Singapore Airlines, and Craig Mundie, Chief Research and Strategy Officer of Microsoft.  Terms of the investment were not disclosed.

"It's fantastic to have so many investors from the original consortium come back for this follow-on investment round," said Van Crocker, Vice President of Commercial Development for AuraSense Therapeutics.  "This financing shows the faith our investors have in the technology, the team and our progress to date.  We look forward to taking our first SNA constructs through the preclinical development phase."

Schiff Hardin LLP served as deal counsel to AuraSense Therapeutics for the investment transaction.

About AuraSense Therapeutics, LLC

AuraSense Therapeutics, LLC is a privately held biopharmaceutical company founded by Professors Chad A. Mirkin and C. Shad Thaxton of Northwestern University.  Headquartered in Skokie, Illinois, the Company is dedicated to developing and commercializing spherical nucleic acid (SNA™) conjugates.  Its proprietary SNA constructs possess unparalleled biocompatibility and versatility as therapeutics, and they hold great promise for combating the world's most threatening diseases.  The Company's SNA technology overcomes the most difficult obstacles to gene regulation:  genetic targeting with safe and effective in vivo performance.  For additional information about the company, please visit www.aurasensetherapeutics.com.


'/>"/>
SOURCE AuraSense Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Covington Advises Actelion in Acquisition of Ceptaris Therapeutics
2. Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
3. Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth
4. Serina Therapeutics Announces Agreement with the Scripps Research Institute for Development of Polymer-Antibody Drug Conjugates
5. Advanced Prenatal Therapeutics Appoints Dr. Nihar Nayak to its Scientific Advisory Board
6. Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent Oxycodone, PF614
7. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
8. Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
9. Frost & Sullivan: Molecular Farming Fits Need for Fully Functional Protein Therapeutics and Low-Cost Vaccines
10. Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis
11. Distinguished Cancer Investigator, Daniel Von Hoff, M.D., to Lead Cell Therapeutics Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Noom, Inc., ... it will charge enterprise customers only when their members ... the health and wellness sector, which typically charges for ... - http://photos.prnewswire.com/prnh/20161207/446824LOGO ... the power of technology with the empathy of live ...
(Date:12/8/2016)... BRAINTREE, Mass. , Dec. 8, 2016  Haemonetics Corporation ... to NextGen DMS (Donor Management System), an innovative software suite ... operations. The launch of NextGen DMS 4 ... focus including: reducing the cost per liter of plasma collected, ... and improve plasma center operations. ...
(Date:12/8/2016)... -- Stock-Callers.com revisits the Drug Manufacturers industry, ... of pharmaceutical drug products. Companies in this space can ... these firms typically have dividend yields that are higher ... review this morning are: Novo Nordisk A/S (NYSE: ... SGYP ), Pernix Therapeutics Holdings Inc. (NASDAQ: ...
Breaking Medicine Technology:
(Date:12/8/2016)... , ... December 08, 2016 , ... Coppin Insurance Agency, ... and families in and around the Cape Coral area, is embarking on a charity ... Bank of Southwest Florida. , The Harry Chapin Food Bank of Southwest Florida works ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... to families and business owners in and around central Kansas, is joining the ... at-risk youth in the region. , Headquartered in Wichita, Youth Horizons works to ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Today, MHA ... most comprehensive mental health systems reform legislation in more than fifty years. We ... the commitment of our elected officials to improving mental health services and supports ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... treat wrinkles and deep lines by smoothing and tightening the skin of the ... out there to address facial aging with very little downtime, Silhouette Instalift is ...
(Date:12/7/2016)... ... December 07, 2016 , ... EnghouseSystems ... purchase price of approximately $17.4 million (net of the cash acquired), subject ... $13.2 million. Headquartered in Barcelona, Spain, Presence is a leading provider of ...
Breaking Medicine News(10 mins):